AWM
PRLD icon

Avior Wealth Management’s Prelude Therapeutics PRLD Stock Holding History

Avior Wealth Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$4 – 3349
2024
Q1 		$4 Buy
+1
New +$4 ﹤0.01% 3814

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Avior Wealth Management's PRLD Position: Q2 2024 in Review

Avior Wealth Management sold out of Prelude Therapeutics (PRLD) in Q2 2024, closing a stake of 1 share — an estimated $4 sold.

Avior Wealth Management first reported a position in PRLD in Q1 2024 and held it in 1 quarter. The position peaked at $4 in Q1 2024. 61 funds tracked by Wall St. Rank hold PRLD as of Q2 2024.

  • Avior Wealth Management reported no remaining Prelude Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 1 Prelude Therapeutics share in Q2 2024, an estimated $4.
  • Avior Wealth Management first reported a position in Prelude Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Prelude Therapeutics position peaked at $4 in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.